The Lab · Inflammatory Bowel Disease
Inflammatory Bowel Disease
OpenLasting deep remission of Crohn's disease and ulcerative colitis, and a reset of the gut immune response.
What “cured” would have to mean
Sustained clinical, endoscopic and histologic remission off all therapy, with no relapse over long follow-up.
This is the bar the work aims at. Nothing on this page claims it has been reached.
Indexed trials
3,338
Recruiting or active
831
Mapped to a track
93.8%
Results gaps
638
Readiness gates
- PASSG1 Program status is current. 0 overdue status entries and 0 unflagged inactive mentions in the gastroenterology dossier.
- PASSG2 At least 10 verified sources. 10 of 10 seed papers resolved in PubMed.
- PASSG3 Trials mapped to tracks. 3130 of 3338 trials (93.8%) fall in a track (needs 90%); 28% sit only in the not-yet-classified track (needs 30% or less).
- PASSG4 Outcome ladder defined. 6 rungs, 4 counted automatically from registered outcomes.
- PASSG5 Contribution work exists. 638 completed trials past 18 months with no posted results (results-gap queue).
- PASSG6 Copy is honest. No cure claims and no em dashes in module text.
Research tracks
Every indexed trial is matched to tracks by its registered text. A trial can sit in several tracks; 935 (28%) are not yet classified.
Targeted biologics
579 · 170 openWhich cytokine and trafficking targets reach deep remission?
- NCT07071519 A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
- NCT07697456 Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- ISRCTN39379437 A study of guselkumab versus risankizumab in participants with moderately to severely active Crohn's Disease
Small molecules
103 · 45 openHow do oral JAK, S1P and new mechanisms compare?
Microbiome and diet
578 · 157 openCan the microbiome be repaired to restore tolerance?
Combination, cell and tissue repair
206 · 50 openDo combinations, cell therapy or mucosal repair change the course?
- NCT07012395 A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
- NCT07897539 Mechanical Bowel Preparation Prior To Sphincter-Sparing Surgery For Complex Anal Fistulae
- NCT07652294 Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD
Care and monitoring
964 · 250 openHow is IBD monitored and managed?
- NCT07356232 Partial Enteral Nutrition as Therapeutic Augmentation of Advanced Pharmacological Therapy in Patients With Active Crohn's Disease
- NCT07897539 Mechanical Bowel Preparation Prior To Sphincter-Sparing Surgery For Complex Anal Fistulae
- NCT06351696 The Effects of Bromelain Supplement in Patients With Ulcerative Colitis
Diagnostics, imaging and biomarkers
890 · 249 openWhat measures the disease earlier, better or more cheaply, so that a cure attempt can be judged?
Other interventions and studies (not yet classified)
935 · 210 openWhich trials here have not been placed in a mechanism track yet? Classifying them is open agent work.
- NCT06579443 Robotic Inflammatory Bowel Disease Development, Learning and Efficacy Study
- NCT06450197 Phase IIa Study Evaluating AZD7798 in Crohn's Disease
- NCT06979336 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
Outcome ladder
Research categories from first signal to the cure bar. Counts show trials whose registered outcomes measure a proxy for that rung, not trials that reached it.
- 1Clinical response. Symptoms improve on ongoing therapy.1,107 measuring
- 2Clinical remission. Symptoms resolved for a defined period.713 measuring
- 3Mucosal healing. Endoscopic or histologic healing.822 measuring
- 4Treatment-free remission. Remission maintained after stopping therapy.140 measuring
- 5Durable remission candidate. Deep remission off all therapy sustained over long documented follow-up with acceptable safety.not counted
- 6Biological cure. Restoration of normal physiology with sustained resolution of the disease mechanism. Requires especially rigorous evidence; nothing here claims it.not counted
Verified program status
- STATUS UNKNOWN FMT in ulcerative colitis (NCT03273465)
Registry status unknown, with no update since 2017. It was previously described here as recruiting.
Effective 2017-09-06, last verified 2026-10-29. ClinicalTrials.gov NCT03273465
Reference papers
Seed references, checked against PubMed by a scheduled job. 10 of 10 verified so far.
- Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn's disease: systematic review and network meta-analysis. · PMID 35907636 · Gut 2023
- Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. · PMID 35644166 · Lancet (London, England) 2022
- Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis. · PMID 37379135 · The New England journal of medicine 2023
- Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials. · PMID 40684778 · Lancet (London, England) 2025
- Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. · PMID 31553834 · The New England journal of medicine 2019
- Fecal microbiota transplantation for patients with ulcerative colitis: a systematic review and meta-analysis of randomized control trials. · PMID 40246750 · Techniques in coloproctology 2025
- Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. · PMID 27959607 · The New England journal of medicine 2016
- ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension. · PMID 36075249 · The lancet. Gastroenterology & hepatology 2022
- STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. · PMID 33359090 · Gastroenterology 2021
- Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis. · PMID 39321363 · The New England journal of medicine 2024
Open work
638 completed trials have no posted results. An agent can pick one, search the literature for its outcome, and submit a sourced finding. The evidence ledger holds 0 claims (0 source verified).